Home Blog of Signal Transduction Metabolism HMG-CoA Reductase

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

HMG-CoA Reductase

Statins protect mice from high-decibel noise-induced hearing loss

49 views | Nov 04 2023

The study found that direct delivery of fluvastatin to the cochlea and oral administration of lovastatin showed potential protective effects against noise-induced hearing loss in CBA/CaJ mice, as evidenced by reduced threshold shifts in auditory brainstem responses. [Read the Full Post]

The effect of lipid-lowering therapies on the pro-inflammatory and anti-inflammatory properties of vascular endothelial cells

79 views | Mar 16 2023

The study found that both statins, particularly rosuvastatin, had a stronger anti-inflammatory effect than ezetimibe in endothelial cells damaged by 25-hydroxycholesterol. [Read the Full Post]

Significance of Basal Membrane Permeability of Epithelial Cells in Predicting Intestinal Drug Absorption

101 views | Mar 15 2023

The study showed that assessing the permeability of A and B membranes separately and accounting for the intracellular drug concentration can improve the accuracy of predicting drug absorption in the gastrointestinal tract and understanding the role of transporters and enzymes. [Read the Full Post]

Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies

75 views | Mar 15 2023

This review highlights the mechanisms of paclitaxel and docetaxel resistance in prostate cancer and discusses the potential of phytochemicals and nanostructures for reversing drug resistance. [Read the Full Post]

Mechanistic in vitro studies indicate that the clinical drug-drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3

65 views | Mar 15 2023

This passage describes the use of a mechanistic static model to reconcile the disconnect between predicted and clinically observed area under the plasma concentration-time curve ratio (AUCR) of rosuvastatin due to drug-drug interaction (DDI) with atazanavir, by evaluating the inhibitory effects of atazanavir and other protease inhibitors on additional transporters, and integrating a combined hepatic transport component into the model. [Read the Full Post]

Treating linear porokeratosis with topical lovastatin/cholesterol cream

125 views | Mar 14 2023

Linear porokeratosis is a rare skin condition characterized by unilateral linear lesions that follow the lines of Blaschko and is currently treated with therapies aimed at restoring the mevalonate biosynthesis pathway and keratinocyte cholesterol availability, such as compounded 2% lovastatin/2% cholesterol cream. [Read the Full Post]

Assessment of the regenerative potential of macro-porous chitosan-calcium simvastatin scaffolds on bone cells

136 views | Mar 08 2023

The study evaluated the bioactive potential of a macro-porous chitosan scaffold incorporated with calcium hydroxide and functionalized with bioactive doses of simvastatin for bone tissue regeneration, demonstrating increased bioactivity and promising potential. [Read the Full Post]

Impacts of Statin Therapy Strategies on Incidence of Ischemic Cerebrovascular Events in Patients With Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Bayesian Network Meta-Analysis

76 views | Mar 08 2023

The Bayesian network meta-analysis and systematic review suggest that statins can significantly improve functional prognosis and reduce the incidence of ischemic cerebrovascular events in patients with aSAH, with pravastatin (40 mg/d) being the most effective type of statin. [Read the Full Post]

Chemotherapeutic Activity of Pitavastatin in Vincristine Resistant B-Cell Acute Lymphoblastic Leukemia

98 views | Mar 07 2023

The study suggests that pitavastatin may have potential as a repurposed chemotherapeutic agent for vincristine-resistant B-cell acute lymphoblastic leukemia. [Read the Full Post]

Effect of concomitant use of pitavastatin with neoadjuvant chemotherapy protocols in breast cancer patients: A randomized controlled clinical trial

158 views | Nov 21 2022

Samar A Dewidar et al. thought that concomitant use of pitavastatin with standard neoadjuvant chemotherapy protocols might improve neoadjuvant chemotherapy responses in patients with breast cancer. [Read the Full Post]